|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2025―Apr―21 |
SARS-COV-2-vaccine-inactivated |
|
2 |
[GO] |
2025―Apr―21 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
3 |
[GO] |
2025―Apr―11 |
COVID-19-vaccine/Olanzapine/Risperidone |
|
4 |
[GO] |
2025―Apr―05 |
COVID-19 vaccine-related cerebral venous sinus thrombosis |
|
5 |
[GO] |
2025―Mar―29 |
COVID-19-vaccine |
|
6 |
[GO] |
2025―Mar―28 |
COVID-19-vaccine/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
7 |
[GO] |
2025―Mar―14 |
COVID-19-vaccine/Carboplatin/Gemcitabine |
|
8 |
[GO] |
2025―Mar―14 |
Use of mABs for COVID-19 increases risk of hepatotoxicity and neutropenia |
|
9 |
[GO] |
2025―Feb―28 |
COVID-19-vaccine/elasomeran/tozinameran |
|
10 |
[GO] |
2025―Feb―25 |
COVID-19-vaccine |
|
11 |
[GO] |
2025―Feb―25 |
COVID-19-vaccine |
|
12 |
[GO] |
2025―Feb―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
13 |
[GO] |
2025―Feb―10 |
COVID-19-vaccine |
|
14 |
[GO] |
2025―Jan―31 |
COVID-19-vaccine |
|
15 |
[GO] |
2025―Jan―31 |
COVID-19-vaccine |
|
16 |
[GO] |
2025―Jan―24 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/Tozinameran |
|
17 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine/ipilimumab/nivolumab |
|
18 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine |
|
19 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine/imiquimod/prednisolone |
|
20 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine |
|
21 |
[GO] |
2025―Jan―16 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
22 |
[GO] |
2025―Jan―06 |
COVID-19-vaccine |
|
23 |
[GO] |
2025―Jan―06 |
COVID-19-vaccine |
|
24 |
[GO] |
2025―Jan―06 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
25 |
[GO] |
2025―Jan―06 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
26 |
[GO] |
2024―Dec―21 |
COVID-19-vaccines |
|
27 |
[GO] |
2024―Dec―21 |
COVID-19-vaccine |
|
28 |
[GO] |
2024―Dec―07 |
COVID-19-vaccine/Hydrocortisone |
|
29 |
[GO] |
2024―Dec―07 |
COVID-19-vaccine |
|
30 |
[GO] |
2024―Dec―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
31 |
[GO] |
2024―Dec―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
32 |
[GO] |
2024―Nov―28 |
COVID-19-vaccine |
|
33 |
[GO] |
2024―Nov―28 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
34 |
[GO] |
2024―Nov―22 |
COVID-19-vaccine |
|
35 |
[GO] |
2024―Nov―22 |
COVID-19-vaccine/Sunitinib |
|
36 |
[GO] |
2024―Nov―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
37 |
[GO] |
2024―Nov―14 |
COVID-19 vaccine-related AEs in South Korea |
|
38 |
[GO] |
2024―Nov―14 |
COVID-19-vaccine |
|
39 |
[GO] |
2024―Nov―14 |
COVID-19-vaccine/Influenza-virus-vaccine/Tetanus-vaccine |
|
40 |
[GO] |
2024―Nov―14 |
COVID-19-vaccine/Influenza-virus-vaccine/Varicella-zoster-virus-vaccine |
|
41 |
[GO] |
2024―Nov―08 |
COVID-19-vaccine |
|
42 |
[GO] |
2024―Oct―24 |
EGFR-TKI therapy does not increase risk of COVID-19 infection |
|
43 |
[GO] |
2024―Oct―24 |
COVID-19-vaccine |
|
44 |
[GO] |
2024―Oct―18 |
COVID-19-vaccine |
|
45 |
[GO] |
2024―Oct―15 |
COVID-19-vaccine/Influenza-virus-vaccine/Respiratory-syncytial-virus-vaccine |
|
46 |
[GO] |
2024―Oct―04 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
47 |
[GO] |
2024―Sep―26 |
SARS-COV-2 vaccine inactivated Sinovac Biotech/Tozinameran |
|
48 |
[GO] |
2024―Sep―24 |
COVID-19-vaccine |
|
49 |
[GO] |
2024―Sep―24 |
COVID-19-vaccine/Ceftriaxone/Remdesivir |
|
50 |
[GO] |
2024―Sep―24 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
51 |
[GO] |
2024―Sep―19 |
Risk of menorrhagia after mRNA COVID-19 vaccination |
|
52 |
[GO] |
2024―Sep―19 |
COVID-19 vaccine-related myocarditis and myocardial injury |
|
53 |
[GO] |
2024―Sep―19 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
54 |
[GO] |
2024―Aug―24 |
COVID-19-vaccine |
|
55 |
[GO] |
2024―Aug―16 |
Paxlovid, molnupiravir and sotrovimab safe for COVID-19 infections |
|
56 |
[GO] |
2024―Aug―09 |
COVID-19 vaccination-related urinary tract effects |
|
57 |
[GO] |
2024―Aug―09 |
COVID-19 vaccine |
|
58 |
[GO] |
2024―Aug―09 |
COVID-19-vaccine |
|
59 |
[GO] |
2024―Aug―02 |
COVID-19-vaccine/Hyaluronic acid |
|
60 |
[GO] |
2024―Aug―02 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
61 |
[GO] |
2024―Jul―27 |
COVID-19 vaccination in first trimester: no increase in congenital abnormalities |
|
62 |
[GO] |
2024―Jul―27 |
COVID-19 vaccination safe during pregnancy |
|
63 |
[GO] |
2024―Jul―27 |
COVID-19 vaccines |
|
64 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
65 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
66 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
67 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
68 |
[GO] |
2024―Jul―12 |
Long-lasting lymphadenopathy after COVID-19 vaccination |
|
69 |
[GO] |
2024―Jul―12 |
No increase in major birth defects after exposure to mRNA COVID-19 vaccines |
|
70 |
[GO] |
2024―Jul―05 |
mRNA COVID-19 vaccination safe in pregnancy |
|
71 |
[GO] |
2024―Jul―05 |
COVID-19-vaccine |
|
72 |
[GO] |
2024―Jul―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
73 |
[GO] |
2024―Jul―02 |
Safety profile of COVID-19 vaccines favourable in immunocompromised people |
|
74 |
[GO] |
2024―Jul―02 |
COVID-19-vaccine |
|
75 |
[GO] |
2024―Jul―02 |
COVID-19-vaccine |
|
76 |
[GO] |
2024―Jul―02 |
COVID-19-vaccine/Immune-globulin/Steroids |
|
77 |
[GO] |
2024―Jul―02 |
COVID-19-vaccines |
|
78 |
[GO] |
2024―Jul―02 |
Severe acute respiratory syndrome coronavirus-2 mRNA vaccine |
|
79 |
[GO] |
2024―Jul―02 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
80 |
[GO] |
2024―Jun―22 |
AEs after COVID-19 vaccination are associated with nAB response |
|
81 |
[GO] |
2024―Jun―22 |
COVID-19-vaccine |
|
82 |
[GO] |
2024―Jun―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
83 |
[GO] |
2024―Jun―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
84 |
[GO] |
2024―Jun―19 |
COVID-19-vaccine |
|
85 |
[GO] |
2024―May―31 |
BBV-152 COVID-19 vaccine-related AESIs may persist for a year |
|
86 |
[GO] |
2024―May―31 |
COVID-19-vaccine/influenza-virus-vaccine |
|
87 |
[GO] |
2024―May―28 |
COVID-19 vaccines/immunosuppressants |
|
88 |
[GO] |
2024―May―28 |
COVID-19-vaccine |
|
89 |
[GO] |
2024―May―28 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
90 |
[GO] |
2024―May―11 |
PPI use increases risk of COVID-19 infections after two doses of COVID-19 vaccine |
|
91 |
[GO] |
2024―May―11 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
92 |
[GO] |
2024―May―03 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
93 |
[GO] |
2024―May―03 |
COVID-19-vaccine/polymethyl-methacrylate |
|
94 |
[GO] |
2024―May―03 |
COVID-19-vaccine/prednisone/tacrolimus |
|
95 |
[GO] |
2024―May―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
96 |
[GO] |
2024―May―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/Tozinameran |
|
97 |
[GO] |
2024―Apr―27 |
COVID-19 vaccine-related heavy menstrual bleeding |
|
98 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine |
|
99 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine |
|
100 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine |
|
101 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
102 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine/Elasomeran |
|
103 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine/Immune-globulin |
|
104 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine/Olanzapine |
|
105 |
[GO] |
2024―Apr―27 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
106 |
[GO] |
2024―Apr―27 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
107 |
[GO] |
2024―Apr―12 |
Moderna COVID-19 vaccine may cause chronic urticaria |
|
108 |
[GO] |
2024―Apr―12 |
COVID-19 vaccines do not increase GP visits for menstrual disorders |
|
109 |
[GO] |
2024―Apr―12 |
COVID-19-vaccine |
|
110 |
[GO] |
2024―Apr―12 |
COVID-19-vaccine |
|
111 |
[GO] |
2024―Apr―12 |
COVID-19-vaccine/cilgavimab/tixagevimab |
|
112 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine |
|
113 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
114 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine/nirmatrelvir+ritonavir/tacrolimus |
|
115 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine/nirmatrelvir+ritonavir/tacrolimus |
|
116 |
[GO] |
2024―Apr―05 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
117 |
[GO] |
2024―Mar―23 |
COVID-19 Vaccines |
|
118 |
[GO] |
2024―Mar―23 |
mRNA COVID-19 vaccines not linked to postmenopausal bleeding |
|
119 |
[GO] |
2024―Mar―23 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/ibuprofen/paracetamol |
|
120 |
[GO] |
2024―Mar―08 |
Co-administration of bivalent mRNA COVID-19 and influenza vaccines: no new or unexpected safety concerns |
|
121 |
[GO] |
2024―Mar―08 |
COVID-19-vaccines/Immunosuppressants/Rituximab |
|
122 |
[GO] |
2024―Mar―01 |
COVID-19 vaccine-related audiovestibular AEs |
|
123 |
[GO] |
2024―Mar―01 |
COVID-19-vaccine |
|
124 |
[GO] |
2024―Mar―01 |
COVID-19-vaccine |
|
125 |
[GO] |
2024―Mar―01 |
COVID-19-vaccines/Prednisone/Valaciclovir |
|
126 |
[GO] |
2024―Feb―22 |
COVID-19 vaccine |
|
127 |
[GO] |
2024―Feb―22 |
Risks of neonatal AEs after mRNA COVID-19 vaccine exposure |
|
128 |
[GO] |
2024―Feb―22 |
Global COVID-19 vaccine study confirms safety signals |
|
129 |
[GO] |
2024―Feb―09 |
COVID-19-vaccine |
|
130 |
[GO] |
2024―Feb―09 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/thiamazole |
|
131 |
[GO] |
2024―Feb―02 |
Insufficient evidence to link Long COVID to COVID-19 vaccines |
|
132 |
[GO] |
2024―Feb―02 |
In utero exposure to COVID-19 vaccines has no neurodevelopmental impact |
|
133 |
[GO] |
2024―Jan―25 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/hydrocortisone |
|
134 |
[GO] |
2024―Jan―13 |
Differences in rates of AESIs between COVID-19 vaccine types |
|
135 |
[GO] |
2024―Jan―13 |
COVID-19-vaccine |
|
136 |
[GO] |
2024―Jan―13 |
COVID-19-vaccine/lamotrigine |
|
137 |
[GO] |
2024―Jan―13 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
138 |
[GO] |
2024―Jan―13 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
139 |
[GO] |
2024―Jan―05 |
Sudden deafness reported after COVID-19 vaccination |
|
140 |
[GO] |
2024―Jan―05 |
COVID-19 Vaccines |
|
141 |
[GO] |
2024―Jan―05 |
COVID-19-vaccine |
|
142 |
[GO] |
2024―Jan―05 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
143 |
[GO] |
2023―Dec―22 |
No risk of respiratory exacerbation after COVID-19 vaccination |
|
144 |
[GO] |
2023―Dec―14 |
Corticosteroids/cyclophosphamide/severe acute respiratory syndrome coronavirus 2 mRNA vaccine |
|
145 |
[GO] |
2023―Dec―12 |
COVID-19 vaccine |
|
146 |
[GO] |
2023―Dec―12 |
Covid-19-vaccine |
|
147 |
[GO] |
2023―Dec―12 |
COVID-19-vaccine/tamoxifen |
|
148 |
[GO] |
2023―Dec―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
149 |
[GO] |
2023―Dec―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
150 |
[GO] |
2023―Dec―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
151 |
[GO] |
2023―Dec―04 |
COVID-19-vaccine |
|
152 |
[GO] |
2023―Dec―04 |
Covid-19-vaccine/hyaluronic-acid/tozinameran |
|
153 |
[GO] |
2023―Dec―01 |
COVID-19-vaccine |
|
154 |
[GO] |
2023―Dec―01 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
155 |
[GO] |
2023―Nov―25 |
COVID-19 vaccination: large impact on reporting of ADRs not related to COVID-19 vaccines in France |
|
156 |
[GO] |
2023―Nov―25 |
mRNA COVID-19 vaccine: side effects more common, recovery prolonged among females and younger adults |
|
157 |
[GO] |
2023―Nov―25 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immune-globulin |
|
158 |
[GO] |
2023―Nov―25 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
159 |
[GO] |
2023―Nov―09 |
COVID-19 vaccine |
|
160 |
[GO] |
2023―Nov―09 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
161 |
[GO] |
2023―Nov―03 |
Pfizer-BioNTech COVID-19 vaccination safe in adolescents with CKD |
|
162 |
[GO] |
2023―Nov―03 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
163 |
[GO] |
2023―Nov―03 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
164 |
[GO] |
2023―Oct―27 |
ICMRA statement on safety of COVID-19 vaccines |
|
165 |
[GO] |
2023―Oct―27 |
COVID-19-vaccine |
|
166 |
[GO] |
2023―Oct―27 |
Covid-19-vaccine/methotrexate |
|
167 |
[GO] |
2023―Oct―27 |
COVID-19-vaccines |
|
168 |
[GO] |
2023―Oct―19 |
COVID-19-vaccine |
|
169 |
[GO] |
2023―Oct―19 |
Covid-19-vaccine |
|
170 |
[GO] |
2023―Sep―29 |
Severe acute respiratory syndrome coronavirus-2 mRNA vaccine |
|
171 |
[GO] |
2023―Sep―21 |
AstraZeneca COVID-19 vaccine-related pityriasis rosea |
|
172 |
[GO] |
2023―Sep―21 |
AstraZeneca COVID-19 vaccine-related retinal vein occlusion |
|
173 |
[GO] |
2023―Sep―21 |
SARS-COV-2-vaccine-inactivated |
|
174 |
[GO] |
2023―Sep―18 |
COVID-19 vaccination does not increase risk of preterm labour |
|
175 |
[GO] |
2023―Sep―18 |
Safety signal of CIDP with use of AstraZeneca COVID-19 vaccine |
|
176 |
[GO] |
2023―Sep―18 |
COVID-19-vaccine |
|
177 |
[GO] |
2023―Sep―18 |
Covid-19-vaccine |
|
178 |
[GO] |
2023―Sep―18 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
179 |
[GO] |
2023―Sep―18 |
Covid-19-vaccine-pfizer-biontech |
|
180 |
[GO] |
2023―Sep―18 |
COVID-19-vaccines |
|
181 |
[GO] |
2023―Sep―08 |
Antibacterial use prior to COVID-19 vaccination increases risk of COVID-19 infection |
|
182 |
[GO] |
2023―Sep―08 |
Shoulder injury after Pfizer-BioNTech COVID-19 vaccine |
|
183 |
[GO] |
2023―Sep―08 |
COVID-19 vaccine/nirmatrelvir+ritonavir |
|
184 |
[GO] |
2023―Sep―01 |
COVID-19 vaccines/immunosuppressants/Varicella zoster virus vaccine |
|
185 |
[GO] |
2023―Sep―01 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
186 |
[GO] |
2023―Aug―25 |
Low risk of urticaria exacerbation following COVID-19 vaccination |
|
187 |
[GO] |
2023―Aug―25 |
COVID-19 vaccine |
|
188 |
[GO] |
2023―Aug―25 |
Pfizer-BioNTech COVID-19 vaccine increases risk of myocarditis/pericarditis |
|
189 |
[GO] |
2023―Aug―25 |
AEs and rheumatic disease flares after COVID-19 vaccine versus influenza vaccine |
|
190 |
[GO] |
2023―Aug―25 |
Novavax COVID-19 vaccine: no new safety concerns |
|
191 |
[GO] |
2023―Aug―25 |
COVID-19-vaccine |
|
192 |
[GO] |
2023―Aug―25 |
COVID-19-vaccine |
|
193 |
[GO] |
2023―Aug―25 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
194 |
[GO] |
2023―Aug―25 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
195 |
[GO] |
2023―Aug―18 |
Bivalent mRNA COVID-19 booster vaccines safe in adults |
|
196 |
[GO] |
2023―Aug―18 |
Co-administered influenza vaccine and mRNA COVID-19 vaccine safe |
|
197 |
[GO] |
2023―Aug―18 |
COVID-19-vaccine |
|
198 |
[GO] |
2023―Aug―18 |
COVID-19-vaccines/methylprednisolone |
|
199 |
[GO] |
2023―Aug―18 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
200 |
[GO] |
2023―Aug―11 |
Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD |
|
201 |
[GO] |
2023―Aug―11 |
No association between mRNA COVID-19 vaccines and menorrhagia |
|
202 |
[GO] |
2023―Aug―04 |
Covid-19-vaccine |
|
203 |
[GO] |
2023―Jul―28 |
Covid-19-vaccine |
|
204 |
[GO] |
2023―Jul―28 |
COVID-19-vaccine |
|
205 |
[GO] |
2023―Jul―28 |
COVID-19-vaccines/disease-modifying-antirheumatics interaction |
|
206 |
[GO] |
2023―Jul―28 |
Severe acute respiratory syndrome coronavirus 2 mrna vaccine |
|
207 |
[GO] |
2023―Jul―21 |
Societal burden of opioid toxicity-related deaths in the US worsened during COVID-19 pandemic |
|
208 |
[GO] |
2023―Jul―21 |
Immediate ADRs after COVID-19 vaccination in Denmark |
|
209 |
[GO] |
2023―Jul―21 |
Novavax COVID-19 vaccine NVX-CoV2373 safe in older adults |
|
210 |
[GO] |
2023―Jul―21 |
COVID-19 vaccine-related autoimmune haemolytic anaemia |
|
211 |
[GO] |
2023―Jul―21 |
COVID-19 vaccine-related menstruation disorders |
|
212 |
[GO] |
2023―Jul―21 |
Covid-19-vaccine/immune-globulin |
|
213 |
[GO] |
2023―Jul―21 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
214 |
[GO] |
2023―Jul―14 |
No major differences in AEs between COVID-19 vaccination schedules |
|
215 |
[GO] |
2023―Jul―14 |
EMA endorses statement on safety of COVID-19 vaccines issued by ICMRA |
|
216 |
[GO] |
2023―Jul―14 |
COVID-19-vaccine/dexamethasone/tocilizumab |
|
217 |
[GO] |
2023―Jul―14 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
218 |
[GO] |
2023―Jul―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/zf-2001 |
|
219 |
[GO] |
2023―Jul―07 |
COVID-19 vaccine-related hypersensitivity: basophil reactivity |
|
220 |
[GO] |
2023―Jul―07 |
EMA publishes report on ensuring safety of COVID-19 vaccines |
|
221 |
[GO] |
2023―Jul―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
222 |
[GO] |
2023―Jul―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
223 |
[GO] |
2023―Jun―30 |
COVID-19-vaccine |
|
224 |
[GO] |
2023―Jun―30 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
225 |
[GO] |
2023―Jun―30 |
Covid-19-vaccine |
|
226 |
[GO] |
2023―Jun―30 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
227 |
[GO] |
2023―Jun―23 |
Covid-19-vaccine/fondaparinux-sodium |
|
228 |
[GO] |
2023―Jun―23 |
COVID-19 vaccination and cyclophosphamide |
|
229 |
[GO] |
2023―Jun―23 |
Transverse myelitis after COVID-19 vaccination |
|
230 |
[GO] |
2023―Jun―23 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
231 |
[GO] |
2023―Jun―23 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
232 |
[GO] |
2023―Jun―16 |
Covid-19-vaccine |
|
233 |
[GO] |
2023―Jun―16 |
Covid-19-vaccine |
|
234 |
[GO] |
2023―Jun―16 |
COVID-19 vaccines |
|
235 |
[GO] |
2023―Jun―16 |
Third mRNA COVID-19 vaccine dose well tolerated in infants and young children |
|
236 |
[GO] |
2023―Jun―16 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
237 |
[GO] |
2023―Jun―09 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
238 |
[GO] |
2023―Jun―09 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/dabigatran-etexilate/dipyrone |
|
239 |
[GO] |
2023―Jun―09 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
240 |
[GO] |
2023―Jun―02 |
Covid-19-vaccine |
|
241 |
[GO] |
2023―Jun―02 |
Covid-19-vaccine |
|
242 |
[GO] |
2023―Jun―02 |
Covid-19-vaccine |
|
243 |
[GO] |
2023―Jun―02 |
BNT162b2 COVID-19 vaccine safe in children, signal for myocarditis/pericarditis in adolescents |
|
244 |
[GO] |
2023―May―26 |
COVID-19-vaccine |
|
245 |
[GO] |
2023―May―18 |
Covid-19-vaccine/nirmatrelvir+ritonavir/tacrolimus |
|
246 |
[GO] |
2023―May―18 |
Covid-19-vaccine |
|
247 |
[GO] |
2023―May―18 |
Nirmatrelvir+ritonavir-related AEs in patients with COVID-19 infections |
|
248 |
[GO] |
2023―May―18 |
Associations between COVID-19 vaccination and menstruation disorders "weak and inconsistent" |
|
249 |
[GO] |
2023―May―18 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
250 |
[GO] |
2023―May―18 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
251 |
[GO] |
2023―May―12 |
Covid-19-vaccine |
|
252 |
[GO] |
2023―May―12 |
Covid-19-vaccine |
|
253 |
[GO] |
2023―May―12 |
COVID-19-vaccine/dexamethasone |
|
254 |
[GO] |
2023―May―12 |
Covid-19-vaccine |
|
255 |
[GO] |
2023―May―12 |
Long-term safety of AstraZeneca COVID-19 vaccine |
|
256 |
[GO] |
2023―May―05 |
COVID-19-vaccines |
|
257 |
[GO] |
2023―May―05 |
COVID-19 vaccine-related ADRs in children and adolescents |
|
258 |
[GO] |
2023―May―05 |
COVID-19 vaccine in adolescents: no new serious safety concerns identified |
|
259 |
[GO] |
2023―May―05 |
Viral vector-based COVID-19 vaccines: risk of thrombosis with thrombocytopenia |
|
260 |
[GO] |
2023―May―05 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
261 |
[GO] |
2023―Apr―28 |
COVID-19-vaccines |
|
262 |
[GO] |
2023―Apr―28 |
COVID-19-vaccine/nivolumab |
|
263 |
[GO] |
2023―Apr―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
264 |
[GO] |
2023―Apr―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
265 |
[GO] |
2023―Apr―28 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
266 |
[GO] |
2023―Apr―21 |
COVID-19-vaccines |
|
267 |
[GO] |
2023―Apr―21 |
Covid-19-vaccine |
|
268 |
[GO] |
2023―Apr―21 |
Covid-19 vaccines |
|
269 |
[GO] |
2023―Apr―21 |
Vulval aphthous ulcers in adolescents after COVID-19 vaccination |
|
270 |
[GO] |
2023―Apr―21 |
mRNA COVID-19 vaccination not associated with retinal vascular occlusion |
|
271 |
[GO] |
2023―Apr―14 |
COVID-19-vaccines/glucocorticoids |
|
272 |
[GO] |
2023―Apr―14 |
Covid-19-vaccine/nirmatrelvir/ritonavir |
|
273 |
[GO] |
2023―Apr―14 |
COVID-19-vaccine/elasomeran |
|
274 |
[GO] |
2023―Apr―14 |
Covid-19 vaccine |
|
275 |
[GO] |
2023―Apr―14 |
COVID-19 vaccination: serious AEs and AESIs rare |
|
276 |
[GO] |
2023―Apr―06 |
Covid-19-vaccine |
|
277 |
[GO] |
2023―Apr―06 |
COVID-19 vaccination safety during pregnancy |
|
278 |
[GO] |
2023―Apr―06 |
Experiences after first COVID-19 vaccination impact severity of AEs after second dose |
|
279 |
[GO] |
2023―Apr―06 |
SARS-Cov-2-vaccine-inactivated-Sinovac-Biotech |
|
280 |
[GO] |
2023―Apr―06 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
281 |
[GO] |
2023―Mar―31 |
Covid-19-vaccine |
|
282 |
[GO] |
2023―Mar―31 |
Covid-19-vaccine |
|
283 |
[GO] |
2023―Mar―31 |
COVID-19-vaccine |
|
284 |
[GO] |
2023―Mar―31 |
SARS-COV-2-vaccine-inactivated |
|
285 |
[GO] |
2023―Mar―31 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
286 |
[GO] |
2023―Mar―25 |
Covid-19-vaccine/elasomeran/tozinameran |
|
287 |
[GO] |
2023―Mar―25 |
Covid-19-vaccine/obinutuzumab |
|
288 |
[GO] |
2023―Mar―25 |
Covid-19-vaccine-pfizer-biontech |
|
289 |
[GO] |
2023―Mar―25 |
COVID-19-vaccine |
|
290 |
[GO] |
2023―Mar―25 |
Covid-19 vaccine |
|
291 |
[GO] |
2023―Mar―23 |
Covid-19-vaccine |
|
292 |
[GO] |
2023―Mar―23 |
Covid-19-vaccine |
|
293 |
[GO] |
2023―Mar―23 |
COVID-19-vaccine |
|
294 |
[GO] |
2023―Mar―23 |
Covid-19-vaccine |
|
295 |
[GO] |
2023―Mar―23 |
COVID-19 vaccine-related Guillain-Barre syndrome |
|
296 |
[GO] |
2023―Mar―10 |
COVID-19 vaccine |
|
297 |
[GO] |
2023―Mar―10 |
Anxiety and depression increase risk of reporting COVID-19 vaccine-related AEs |
|
298 |
[GO] |
2023―Mar―10 |
Covid-19-vaccine |
|
299 |
[GO] |
2023―Mar―10 |
Sars-cov-2 vaccine-inactivated-sinovac-biotech |
|
300 |
[GO] |
2023―Mar―10 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
301 |
[GO] |
2023―Mar―03 |
African countries report fewer AEFIs after COVID-19 vaccination than RoW |
|
302 |
[GO] |
2023―Mar―03 |
COVID-19 vaccine |
|
303 |
[GO] |
2023―Mar―03 |
Novavax COVID-19 vaccine-related myocarditis/pericarditis |
|
304 |
[GO] |
2023―Mar―03 |
HPRA safety update on COVID-19 vaccines up to January 2023 |
|
305 |
[GO] |
2023―Mar―03 |
COVID-19-vaccine |
|
306 |
[GO] |
2023―Mar―03 |
COVID-19-vaccine/rosuvastatin |
|
307 |
[GO] |
2023―Mar―03 |
COVID-19-vaccines/fondaparinux-sodium/mannitol |
|
308 |
[GO] |
2023―Mar―03 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
309 |
[GO] |
2023―Feb―25 |
More AEFIs reported after COVID-19 vaccination in females than in males |
|
310 |
[GO] |
2023―Feb―25 |
COVID-19 vaccine |
|
311 |
[GO] |
2023―Feb―25 |
Covid-19 vaccine/rituximab |
|
312 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
313 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
314 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
315 |
[GO] |
2023―Feb―25 |
Covid-19-vaccine |
|
316 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
317 |
[GO] |
2023―Feb―25 |
Covid-19-vaccine |
|
318 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
319 |
[GO] |
2023―Feb―25 |
Covid-19-vaccines |
|
320 |
[GO] |
2023―Feb―25 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
321 |
[GO] |
2023―Feb―25 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
322 |
[GO] |
2023―Feb―17 |
Adverse events following COVID-19 vaccination common but mild in haemodialysis patients |
|
323 |
[GO] |
2023―Feb―17 |
Covid-19-vaccine |
|
324 |
[GO] |
2023―Feb―17 |
COVID-19-vaccines |
|
325 |
[GO] |
2023―Feb―11 |
COVID-19 rebound after use of Paxlovid |
|
326 |
[GO] |
2023―Feb―11 |
Pregnant women have known AEs after COVID-19 vaccination |
|
327 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine |
|
328 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine |
|
329 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine |
|
330 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine/rituximab |
|
331 |
[GO] |
2023―Feb―11 |
Covid-19-vaccine |
|
332 |
[GO] |
2023―Feb―11 |
COVID-19-vaccine/influenza-virus-vaccine |
|
333 |
[GO] |
2023―Feb―11 |
Covid-19-vaccine/methylprednisolone |
|
334 |
[GO] |
2023―Feb―11 |
COVID-19-vaccines/prednisone |
|
335 |
[GO] |
2023―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
336 |
[GO] |
2023―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
337 |
[GO] |
2023―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
338 |
[GO] |
2023―Feb―11 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
339 |
[GO] |
2023―Feb―03 |
COVID-19-vaccine |
|
340 |
[GO] |
2023―Feb―03 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
341 |
[GO] |
2023―Jan―30 |
Safety of co-administered mRNA COVID-19 and influenza vaccines |
|
342 |
[GO] |
2023―Jan―30 |
Cilgavimab/tixagevimab unlikely to be active against some COVID-19 Omicron subvariants |
|
343 |
[GO] |
2023―Jan―30 |
COVID-19 vaccine |
|
344 |
[GO] |
2023―Jan―30 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
345 |
[GO] |
2023―Jan―30 |
COVID-19-vaccine/nirmatrelvir+ritonavir |
|
346 |
[GO] |
2023―Jan―20 |
Thyroid dysfunction after COVID-19 vaccination |
|
347 |
[GO] |
2023―Jan―20 |
COVID-19-vaccine |
|
348 |
[GO] |
2023―Jan―20 |
COVID-19-vaccine |
|
349 |
[GO] |
2023―Jan―20 |
COVID-19-vaccines/dexamethasone/tocilizumab |
|
350 |
[GO] |
2023―Jan―20 |
Sars-cov-2-vaccine inactivated sinovac biotech |
|
351 |
[GO] |
2023―Jan―20 |
Sars-cov-2-vaccine inactivated sinovac biotech |
|
352 |
[GO] |
2023―Jan―15 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university |
|
353 |
[GO] |
2023―Jan―15 |
Covid-19-vaccine |
|
354 |
[GO] |
2023―Jan―15 |
Covid-19-vaccine/tozinameran |
|
355 |
[GO] |
2023―Jan―15 |
No new safety signals after COVID-19 vaccination in New Zealand |
|
356 |
[GO] |
2023―Jan―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
357 |
[GO] |
2023―Jan―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
358 |
[GO] |
2023―Jan―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
359 |
[GO] |
2023―Jan―14 |
COVID-19-vaccines |
|
360 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine-pfizer-biontech/remdesivir |
|
361 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine/peginterferon-alfa-2a |
|
362 |
[GO] |
2023―Jan―14 |
COVID-19-vaccine |
|
363 |
[GO] |
2023―Jan―14 |
COVID-19-vaccine |
|
364 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
365 |
[GO] |
2023―Jan―14 |
COVID-19-vaccine |
|
366 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
367 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
368 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
369 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
370 |
[GO] |
2023―Jan―14 |
COVID-19 vaccines |
|
371 |
[GO] |
2023―Jan―14 |
POTS less frequent after COVID-19 vaccine than after COVID infection |
|
372 |
[GO] |
2023―Jan―14 |
COVID-19 vaccine |
|
373 |
[GO] |
2022―Dec―16 |
ADRs following use of oral COVID-19 therapeutics (Paxlovid, Lagevrio) in New Zealand |
|
374 |
[GO] |
2022―Dec―16 |
Covid-19-vaccine |
|
375 |
[GO] |
2022―Dec―16 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
376 |
[GO] |
2022―Dec―16 |
Sars-cov-2-vaccine-inactivated |
|
377 |
[GO] |
2022―Dec―10 |
FDA drug safety surveillance during COVID-19 pandemic |
|
378 |
[GO] |
2022―Dec―10 |
COVID-19 vaccine |
|
379 |
[GO] |
2022―Dec―10 |
Safety of second Pfizer-BioNTech COVID-19 vaccine booster |
|
380 |
[GO] |
2022―Dec―10 |
Covid-19-vaccine |
|
381 |
[GO] |
2022―Dec―10 |
Covid-19-vaccine |
|
382 |
[GO] |
2022―Dec―10 |
Covid-19-vaccine |
|
383 |
[GO] |
2022―Dec―10 |
Covid-19-vaccine |
|
384 |
[GO] |
2022―Dec―10 |
COVID-19-vaccine/nivolumab/pembrolizumab |
|
385 |
[GO] |
2022―Dec―10 |
Covid-19-vaccine/ocrelizumab |
|
386 |
[GO] |
2022―Dec―10 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
387 |
[GO] |
2022―Dec―10 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
388 |
[GO] |
2022―Dec―02 |
COVID-19 vaccines safe in patients with systemic lupus erythematosus |
|
389 |
[GO] |
2022―Dec―02 |
COVID-19-vaccine |
|
390 |
[GO] |
2022―Dec―02 |
Covid-19-vaccine |
|
391 |
[GO] |
2022―Dec―02 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
392 |
[GO] |
2022―Dec―02 |
Covid-19-vaccine/elasomeran/tozinameran |
|
393 |
[GO] |
2022―Dec―02 |
COVID-19-vaccines/immunosuppressants/tocilizumab |
|
394 |
[GO] |
2022―Nov―28 |
Severe AEs after COVID-19 vaccination following COVID-19 infection |
|
395 |
[GO] |
2022―Nov―28 |
Dedicated system for COVID-19 vaccine safety surveillance at Lareb |
|
396 |
[GO] |
2022―Nov―28 |
COVID-19 vaccine-associated Guillain-Barre syndrome |
|
397 |
[GO] |
2022―Nov―28 |
COVID-19-vaccine |
|
398 |
[GO] |
2022―Nov―28 |
Covid-19-vaccine |
|
399 |
[GO] |
2022―Nov―28 |
COVID-19-vaccines |
|
400 |
[GO] |
2022―Nov―28 |
COVID-19-vaccines/prednisone |
|
401 |
[GO] |
2022―Nov―28 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
402 |
[GO] |
2022―Nov―19 |
COVID-19 vaccine-related neuralgic amyotrophy |
|
403 |
[GO] |
2022―Nov―19 |
Pfizer-BioNTech and Moderna COVID-19 vaccines safe in Japan |
|
404 |
[GO] |
2022―Nov―19 |
COVID-19-vaccine |
|
405 |
[GO] |
2022―Nov―19 |
Covid-19-vaccine |
|
406 |
[GO] |
2022―Nov―19 |
COVID-19-vaccine/propylthiouracil |
|
407 |
[GO] |
2022―Nov―11 |
Pfizer-BioNTech COVID-19 vaccination in children: no serious AEs |
|
408 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
409 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
410 |
[GO] |
2022―Nov―11 |
COVID-19-vaccine |
|
411 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
412 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
413 |
[GO] |
2022―Nov―11 |
COVID-19-vaccines |
|
414 |
[GO] |
2022―Nov―07 |
Risks of thrombosis and thromboembolic events after first COVID-19 vaccination |
|
415 |
[GO] |
2022―Nov―07 |
No pregnancy complications after use of mRNA COVID-19 vaccines |
|
416 |
[GO] |
2022―Nov―07 |
Covid-19-vaccine |
|
417 |
[GO] |
2022―Nov―07 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
418 |
[GO] |
2022―Nov―07 |
COVID-19-vaccines/immune-globulin/methylprednisolone |
|
419 |
[GO] |
2022―Oct―28 |
AEs in children after Pfizer-BioNTech COVID-19 vaccine |
|
420 |
[GO] |
2022―Oct―28 |
Safety of BNT162b2 COVID-19 vaccine comparable to that of other approved vaccines in young children |
|
421 |
[GO] |
2022―Oct―28 |
Risk of COVID-19 vaccine-related tinnitus |
|
422 |
[GO] |
2022―Oct―28 |
Covid-19-vaccine |
|
423 |
[GO] |
2022―Oct―28 |
Covid-19-vaccine |
|
424 |
[GO] |
2022―Oct―28 |
COVID-19-vaccine/immune-globulin/methylprednisolone |
|
425 |
[GO] |
2022―Oct―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
426 |
[GO] |
2022―Oct―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
427 |
[GO] |
2022―Oct―21 |
Multiple sclerosis immunotherapies increase risk of COVID-19 mortality |
|
428 |
[GO] |
2022―Oct―21 |
AEs after COVID-19 vaccination in patients with epilepsy |
|
429 |
[GO] |
2022―Oct―21 |
COVID-19 vaccine-related anaphylaxis and other allergic reactions |
|
430 |
[GO] |
2022―Oct―21 |
COVID-19-vaccine |
|
431 |
[GO] |
2022―Oct―21 |
Covid-19-vaccine |
|
432 |
[GO] |
2022―Oct―21 |
Covid-19-vaccine |
|
433 |
[GO] |
2022―Oct―21 |
Covid-19-vaccine |
|
434 |
[GO] |
2022―Oct―21 |
Covid-19-vaccine |
|
435 |
[GO] |
2022―Oct―21 |
Covid-19-vaccine |
|
436 |
[GO] |
2022―Oct―21 |
COVID-19-vaccine-pfizer-biontech/lisinopril/metoprolol |
|
437 |
[GO] |
2022―Oct―21 |
COVID-19-vaccine/temozolomide |
|
438 |
[GO] |
2022―Oct―21 |
COVID-19-vaccines |
|
439 |
[GO] |
2022―Oct―21 |
COVID-19-vaccines |
|
440 |
[GO] |
2022―Oct―14 |
mRNA COVID-19 vaccine safety in recipients aged 12 to 64 years |
|
441 |
[GO] |
2022―Oct―14 |
Covid-19-vaccine |
|
442 |
[GO] |
2022―Oct―14 |
COVID-19-vaccine |
|
443 |
[GO] |
2022―Oct―14 |
Covid-19-vaccine/elasomeran/tozinameran |
|
444 |
[GO] |
2022―Oct―14 |
Covid-19-vaccine/olanzapine |
|
445 |
[GO] |
2022―Oct―14 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
446 |
[GO] |
2022―Oct―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
447 |
[GO] |
2022―Oct―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
448 |
[GO] |
2022―Oct―07 |
COVID-19 vaccination may trigger tattoo skin reactions |
|
449 |
[GO] |
2022―Oct―07 |
Coronavirus-vaccine |
|
450 |
[GO] |
2022―Oct―07 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university/tozinameran |
|
451 |
[GO] |
2022―Oct―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
452 |
[GO] |
2022―Oct―01 |
Headache common after COVID-19 vaccination |
|
453 |
[GO] |
2022―Oct―01 |
COVID-19 vaccine |
|
454 |
[GO] |
2022―Oct―01 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
455 |
[GO] |
2022―Sep―23 |
Myocardial injury after 4th dose of Pfizer-BioNTech COVID-19 vaccine |
|
456 |
[GO] |
2022―Sep―23 |
Novavax COVID-19 vaccine-related myocarditis and pericarditis |
|
457 |
[GO] |
2022―Sep―23 |
Side effects common after first dose of COVID-19 vaccine: a survey from Spain |
|
458 |
[GO] |
2022―Sep―23 |
COVID-19-vaccine |
|
459 |
[GO] |
2022―Sep―23 |
COVID-19-vaccine |
|
460 |
[GO] |
2022―Sep―23 |
Covid-19-vaccine |
|
461 |
[GO] |
2022―Sep―23 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
462 |
[GO] |
2022―Sep―23 |
Covid-19-vaccine/methotrexate/tumour-necrosis-factor-inhibitors |
|
463 |
[GO] |
2022―Sep―23 |
COVID-19-vaccines/prednisolone/rituximab |
|
464 |
[GO] |
2022―Sep―16 |
COVID-19 outcome not worsened by remdesivir-induced bradycardia |
|
465 |
[GO] |
2022―Sep―16 |
Serious AEs of special interest after mRNA COVID-19 vaccination |
|
466 |
[GO] |
2022―Sep―16 |
COVID-19 vaccine |
|
467 |
[GO] |
2022―Sep―16 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
468 |
[GO] |
2022―Sep―16 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
469 |
[GO] |
2022―Sep―09 |
TTS rare after AstraZeneca COVID-19 vaccine |
|
470 |
[GO] |
2022―Sep―09 |
Safety profile of BBV152 COVID-19 vaccine favourable in adolescents in India |
|
471 |
[GO] |
2022―Sep―09 |
Covid-19-vaccine |
|
472 |
[GO] |
2022―Sep―09 |
Covid-19-vaccine/elasomeran |
|
473 |
[GO] |
2022―Sep―02 |
COVID-19 vaccination safe during pregnancy |
|
474 |
[GO] |
2022―Sep―02 |
COVID-19 vaccine |
|
475 |
[GO] |
2022―Sep―02 |
AstraZeneca, Pfizer-BioNTech, Sinopharm, Sputnik V COVID-19 vaccine |
|
476 |
[GO] |
2022―Sep―02 |
Covid-19 vaccine Gamaleya national research center of epidemiology and microbiology/fenoterol/ipratropium bromide |
|
477 |
[GO] |
2022―Sep―02 |
Adenoviral-based COVID-19 vaccines may increase risk of MI and PE |
|
478 |
[GO] |
2022―Sep―02 |
COVID-19-vaccine |
|
479 |
[GO] |
2022―Sep―02 |
COVID-19-vaccine |
|
480 |
[GO] |
2022―Sep―02 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
481 |
[GO] |
2022―Sep―02 |
SARS-COV-2 vaccine-inactivated Sinovac-Biotech |
|
482 |
[GO] |
2022―Sep―02 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
483 |
[GO] |
2022―Aug―26 |
COVID-19 mRNA vaccines safe in pregnancy |
|
484 |
[GO] |
2022―Aug―26 |
COVID-19 vaccination hesitancy may drive AE reporting |
|
485 |
[GO] |
2022―Aug―26 |
Novavax COVID-19 vaccine-related myocarditis, pericarditis |
|
486 |
[GO] |
2022―Aug―26 |
Covid-19-vaccine |
|
487 |
[GO] |
2022―Aug―26 |
COVID-19-vaccine/dexamethasone/tobramycin |
|
488 |
[GO] |
2022―Aug―19 |
Cutaneous reactions after COVID-19 vaccination |
|
489 |
[GO] |
2022―Aug―19 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
490 |
[GO] |
2022―Aug―19 |
COVID-19-vaccines/immune globulin |
|
491 |
[GO] |
2022―Aug―12 |
Serious AEs uncommon after second mRNA COVID-19 booster |
|
492 |
[GO] |
2022―Aug―12 |
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia case fatalities |
|
493 |
[GO] |
2022―Aug―12 |
COVID-19 vaccines: risk of oral adverse events |
|
494 |
[GO] |
2022―Aug―12 |
Covid-19-vaccine |
|
495 |
[GO] |
2022―Aug―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
496 |
[GO] |
2022―Aug―12 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
497 |
[GO] |
2022―Aug―06 |
Covid-19 vaccine |
|
498 |
[GO] |
2022―Aug―06 |
COVID-19-vaccine |
|
499 |
[GO] |
2022―Jul―29 |
Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons |
|
500 |
[GO] |
2022―Jul―29 |
COVID-19 vaccination: reports of Bell's palsy |
|
501 |
[GO] |
2022―Jul―29 |
COVID-19 vaccine |
|
502 |
[GO] |
2022―Jul―29 |
COVID-19 vaccine: risk of increased menstrual bleeding |
|
503 |
[GO] |
2022―Jul―29 |
COVID-19-vaccine |
|
504 |
[GO] |
2022―Jul―29 |
COVID-19-vaccine/ipilimumab/nivolumab |
|
505 |
[GO] |
2022―Jul―29 |
COVID-19-vaccines |
|
506 |
[GO] |
2022―Jul―23 |
Covid-19-vaccine |
|
507 |
[GO] |
2022―Jul―23 |
COVID-19-vaccine |
|
508 |
[GO] |
2022―Jul―23 |
Sars-cov-2 vaccine inactivated Sinovac Biotech/tozinameran |
|
509 |
[GO] |
2022―Jul―15 |
Covid-19 vaccine |
|
510 |
[GO] |
2022―Jul―15 |
Active surveillance confirms short-term safety of COVID-19 vaccines in Australia |
|
511 |
[GO] |
2022―Jul―15 |
COVID-19 vaccines: reports of lichen planus |
|
512 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine |
|
513 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine |
|
514 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine |
|
515 |
[GO] |
2022―Jul―15 |
COVID-19-vaccine |
|
516 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine-pfizer-biontech/elasomeran |
|
517 |
[GO] |
2022―Jul―15 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
518 |
[GO] |
2022―Jul―08 |
Myocarditis/pericarditis rare after COVID-19 mRNA vaccination |
|
519 |
[GO] |
2022―Jul―08 |
Covid-19 vaccine pfizer biontech |
|
520 |
[GO] |
2022―Jul―08 |
Covid-19 vaccine pfizer biontech |
|
521 |
[GO] |
2022―Jul―08 |
Covid-19-vaccine |
|
522 |
[GO] |
2022―Jul―08 |
Covid-19-vaccine |
|
523 |
[GO] |
2022―Jul―08 |
COVID-19-vaccine |
|
524 |
[GO] |
2022―Jul―08 |
SARS-COV-2-vaccine inactivated Sinovac Biotech |
|
525 |
[GO] |
2022―Jul―08 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
526 |
[GO] |
2022―Jul―08 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
527 |
[GO] |
2022―Jul―01 |
Covid-19 vaccine |
|
528 |
[GO] |
2022―Jul―01 |
COVID-19 vaccine Pfizer BioNTech |
|
529 |
[GO] |
2022―Jul―01 |
Signal detection of COVID-19 vaccine-related AEs |
|
530 |
[GO] |
2022―Jul―01 |
COVID-19-vaccine |
|
531 |
[GO] |
2022―Jul―01 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
532 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-Pfizer-BioNTech |
|
533 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech |
|
534 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech |
|
535 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech |
|
536 |
[GO] |
2022―Jul―01 |
COVID-19-vaccine-Pfizer-Biontech/elasomeran |
|
537 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech/olanzapine/tetrabenazine |
|
538 |
[GO] |
2022―Jul―01 |
COVID-19-vaccines/immunosuppressants |
|
539 |
[GO] |
2022―Jul―01 |
SARS-CoV-2 vaccine inactivated Sinovac Biotech |
|
540 |
[GO] |
2022―Jul―01 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
541 |
[GO] |
2022―Jun―23 |
Acute neurological AEs after COVID-19 vaccination |
|
542 |
[GO] |
2022―Jun―23 |
COVID-19 vaccination and risk of neuralgic amyotrophy |
|
543 |
[GO] |
2022―Jun―23 |
COVID-19 vaccination relatively safe in autoimmune diseases |
|
544 |
[GO] |
2022―Jun―23 |
COVID-19 vaccines/mycophenolate mofetil |
|
545 |
[GO] |
2022―Jun―23 |
Sars-cov-2-vaccine-inactivated |
|
546 |
[GO] |
2022―Jun―23 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
547 |
[GO] |
2022―Jun―23 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
548 |
[GO] |
2022―Jun―23 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
549 |
[GO] |
2022―Jun―17 |
Risk of myocarditis or pericarditis after COVID-19 mRNA vaccines |
|
550 |
[GO] |
2022―Jun―17 |
Risk of Guillain-Barre Syndrome after COVID-19 vaccination |
|
551 |
[GO] |
2022―Jun―17 |
Janssen COVID-19 vaccine increases risk of thrombocytopenia |
|
552 |
[GO] |
2022―Jun―17 |
COVID-19 vaccine-Pfizer-BioNTech |
|
553 |
[GO] |
2022―Jun―17 |
Covid-19-vaccine first report |
|
554 |
[GO] |
2022―Jun―17 |
Covid-19-vaccine-pfizer-biontech |
|
555 |
[GO] |
2022―Jun―17 |
SARS-COV-2-vaccine-inactivated Sinovac-Biotech |
|
556 |
[GO] |
2022―Jun―17 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
557 |
[GO] |
2022―Jun―17 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
558 |
[GO] |
2022―Jun―10 |
AEs after homologous versus heterologous COVID-19 booster |
|
559 |
[GO] |
2022―Jun―10 |
Standardised assessment of COVID-19 vaccine-related skin reactions |
|
560 |
[GO] |
2022―Jun―10 |
Safety of mRNA COVID-19 vaccines during pregnancy |
|
561 |
[GO] |
2022―Jun―10 |
Covid-19-vaccine/lamotrigine |
|
562 |
[GO] |
2022―Jun―03 |
Low risk of myopericarditis after COVID-19 vaccination in children aged 5-11 years |
|
563 |
[GO] |
2022―Jun―03 |
Pfizer-BioNTech COVID-19 vaccine safe with clozapine |
|
564 |
[GO] |
2022―Jun―03 |
COVID-19 vaccine-induced VITT/TSS in Malaysia |
|
565 |
[GO] |
2022―Jun―03 |
Lareb study on COVID-19 vaccine-related menstrual disorders |
|
566 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine |
|
567 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine |
|
568 |
[GO] |
2022―Jun―03 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
569 |
[GO] |
2022―Jun―03 |
Covid-19-vaccine-pfizer-biontech |
|
570 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine-Pfizer-BioNtech |
|
571 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
572 |
[GO] |
2022―Jun―03 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
573 |
[GO] |
2022―Jun―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
574 |
[GO] |
2022―Jun―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
575 |
[GO] |
2022―May―27 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
576 |
[GO] |
2022―May―27 |
Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated |
|
577 |
[GO] |
2022―May―27 |
Pfizer-BioNTech COVID-19 vaccine safe in children |
|
578 |
[GO] |
2022―May―27 |
Covid-19-vaccine |
|
579 |
[GO] |
2022―May―27 |
Covid-19-vaccine |
|
580 |
[GO] |
2022―May―27 |
Covid-19-vaccine |
|
581 |
[GO] |
2022―May―27 |
Covid-19-vaccine-pfizer-biontech |
|
582 |
[GO] |
2022―May―27 |
Covid-19-vaccine-pfizer-biontech/elasomeran |
|
583 |
[GO] |
2022―May―20 |
ADRs due to off-label use of hydroxychloroquine for COVID-19 |
|
584 |
[GO] |
2022―May―20 |
Survey of adverse events following ChAdOx1 COVID-19 vaccination in Ethiopia |
|
585 |
[GO] |
2022―May―20 |
COVID-19-vaccine |
|
586 |
[GO] |
2022―May―20 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immunosuppressants |
|
587 |
[GO] |
2022―May―20 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
588 |
[GO] |
2022―May―20 |
Covid-19-vaccine-pfizer-biontech |
|
589 |
[GO] |
2022―May―20 |
Covid-19-vaccine-pfizer-biontech/levothyroxine-sodium/sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
590 |
[GO] |
2022―May―20 |
COVID-19-vaccines/budesonide/mesalazine |
|
591 |
[GO] |
2022―May―13 |
FDA limits authorised use of Janssen COVID-19 vaccine |
|
592 |
[GO] |
2022―May―13 |
Covid-19-vaccine-pfizer-biontech |
|
593 |
[GO] |
2022―May―13 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
594 |
[GO] |
2022―May―13 |
Covid-19-vaccine-pfizer-biontech |
|
595 |
[GO] |
2022―May―13 |
COVID-19-vaccine/plasma |
|
596 |
[GO] |
2022―May―13 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
597 |
[GO] |
2022―May―06 |
COVID-19 vaccination may reactivate varicella-zoster virus |
|
598 |
[GO] |
2022―May―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
599 |
[GO] |
2022―May―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
600 |
[GO] |
2022―Apr―29 |
No increased risk for venous thromboembolism after COVID-19 vaccination |
|
601 |
[GO] |
2022―Apr―29 |
Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed |
|
602 |
[GO] |
2022―Apr―29 |
COVID-19 vaccine Gamaleya National Research Center of Epidemiology and Microbiology |
|
603 |
[GO] |
2022―Apr―29 |
COVID-19 Vaccine Pfizer BioNTech |
|
604 |
[GO] |
2022―Apr―29 |
Covid-19-vaccine |
|
605 |
[GO] |
2022―Apr―29 |
COVID-19-Vaccine-Pfizer-BioNTech/pegfilgrastim/pembrolizumab |
|
606 |
[GO] |
2022―Apr―29 |
Covid-19-vaccine/methylprednisolone |
|
607 |
[GO] |
2022―Apr―29 |
COVID-19-vaccine/mycophenolate |
|
608 |
[GO] |
2022―Apr―22 |
Cardiac risks higher after COVID-19 infection than mRNA vaccine |
|
609 |
[GO] |
2022―Apr―22 |
Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients |
|
610 |
[GO] |
2022―Apr―22 |
PRAC meeting highlights April 2022: no link between mRNA COVID-19 vaccines and autoimmune hepatitis |
|
611 |
[GO] |
2022―Apr―22 |
Covid-19-vaccine |
|
612 |
[GO] |
2022―Apr―22 |
Covid-19-vaccine-pfizer-biontech |
|
613 |
[GO] |
2022―Apr―22 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
614 |
[GO] |
2022―Apr―22 |
COVID-19-Vaccine-Pfizer-BioNTech/elasomeran |
|
615 |
[GO] |
2022―Apr―22 |
Covid-19-vaccine-pfizer-biontech/prednisone/valaciclovir |
|
616 |
[GO] |
2022―Apr―22 |
COVID-19-vaccines/immune-globulin/methylprednisolone |
|
617 |
[GO] |
2022―Apr―22 |
Coronavirus-vaccine |
|
618 |
[GO] |
2022―Apr―14 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
619 |
[GO] |
2022―Apr―14 |
Covid-19-vaccine-pfizer-biontech |
|
620 |
[GO] |
2022―Apr―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
621 |
[GO] |
2022―Apr―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
622 |
[GO] |
2022―Apr―08 |
Remdesivir does not increase risk of AKI or ALI in COVID-19 patients |
|
623 |
[GO] |
2022―Apr―08 |
COVID-19 vaccine-Pfizer-BioNTech/methylprednisolone aceponate |
|
624 |
[GO] |
2022―Apr―08 |
No evidence of adverse neurological outcomes from COVID-19 vaccines |
|
625 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine |
|
626 |
[GO] |
2022―Apr―08 |
COVID-19-vaccine |
|
627 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine |
|
628 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine-pfizer-biontech |
|
629 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine-pfizer-biontech |
|
630 |
[GO] |
2022―Apr―08 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
631 |
[GO] |
2022―Apr―08 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
632 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine/evolocumab |
|
633 |
[GO] |
2022―Apr―08 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
634 |
[GO] |
2022―Apr―08 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
635 |
[GO] |
2022―Apr―01 |
No safety signal after COVID-19 vaccination for immune-mediated neurological events |
|
636 |
[GO] |
2022―Apr―01 |
Myocarditis after third dose of Pfizer-BioNTech COVID-19 vaccine |
|
637 |
[GO] |
2022―Apr―01 |
COVID-19-vaccine |
|
638 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine |
|
639 |
[GO] |
2022―Apr―01 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
640 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine-pfizer-biontech |
|
641 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine-pfizer-biontech |
|
642 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine-pfizer-biontech/ibuprofen/paracetamol/meloxicam |
|
643 |
[GO] |
2022―Apr―01 |
Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19? |
|
644 |
[GO] |
2022―Mar―25 |
Systemic AEs common after COVID-19 vaccination |
|
645 |
[GO] |
2022―Mar―25 |
COVID-19 vaccine Gamaleya National Research Center of Epidermiology and Microbiology |
|
646 |
[GO] |
2022―Mar―25 |
Covid-19 vaccine-Pfizer-BioNtech |
|
647 |
[GO] |
2022―Mar―25 |
Covid-19-vaccine |
|
648 |
[GO] |
2022―Mar―25 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/fexofenadine |
|
649 |
[GO] |
2022―Mar―25 |
Covid-19-vaccine-pfizer-biontech |
|
650 |
[GO] |
2022―Mar―25 |
Covid-19-vaccine-pfizer-biontech |
|
651 |
[GO] |
2022―Mar―25 |
Covid-19-vaccine-pfizer-biontech/sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
652 |
[GO] |
2022―Mar―25 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
653 |
[GO] |
2022―Mar―19 |
Covid-19-vaccine-pfizer-biontech |
|
654 |
[GO] |
2022―Mar―19 |
COVID-19-Vaccine-Pfizer-BioNTech/elasomeran |
|
655 |
[GO] |
2022―Mar―19 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
656 |
[GO] |
2022―Mar―19 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
657 |
[GO] |
2022―Mar―19 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
658 |
[GO] |
2022―Mar―11 |
Covid-19-vaccine-pfizer-biontech |
|
659 |
[GO] |
2022―Mar―11 |
Covid-19-vaccine-pfizer-biontech/elasomeran |
|
660 |
[GO] |
2022―Mar―11 |
Coronavirus-vaccine |
|
661 |
[GO] |
2022―Mar―11 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university |
|
662 |
[GO] |
2022―Mar―05 |
Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits |
|
663 |
[GO] |
2022―Mar―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
664 |
[GO] |
2022―Mar―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
665 |
[GO] |
2022―Mar―05 |
COVID-19-vaccine-pfizer-biontech |
|
666 |
[GO] |
2022―Mar―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
667 |
[GO] |
2022―Mar―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
668 |
[GO] |
2022―Mar―05 |
Covid-19-vaccine-pfizer-biontech |
|
669 |
[GO] |
2022―Mar―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
670 |
[GO] |
2022―Mar―05 |
Covid-19-vaccine-pfizer-biontech |
|
671 |
[GO] |
2022―Mar―05 |
Covid-19-vaccine-pfizer-biontech/omalizumab |
|
672 |
[GO] |
2022―Mar―05 |
Covid-19-vaccine/vildagliptin interaction |
|
673 |
[GO] |
2022―Mar―05 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
674 |
[GO] |
2022―Feb―25 |
COVID-19 vaccine |
|
675 |
[GO] |
2022―Feb―25 |
COVID-19 vaccine |
|
676 |
[GO] |
2022―Feb―25 |
COVID-19 vaccine |
|
677 |
[GO] |
2022―Feb―25 |
Covid-19-vaccine |
|
678 |
[GO] |
2022―Feb―25 |
Covid-19-vaccine-pfizer-biontech |
|
679 |
[GO] |
2022―Feb―25 |
Covid-19-vaccine-pfizer-biontech |
|
680 |
[GO] |
2022―Feb―25 |
COVID-19-Vaccine-Pfizer-BioNTech/epinephrine |
|
681 |
[GO] |
2022―Feb―18 |
Increase in thromboembolic ADRs from oral contraceptives during COVID-19 pandemic in Spain |
|
682 |
[GO] |
2022―Feb―18 |
No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine |
|
683 |
[GO] |
2022―Feb―18 |
COVID-19 Vaccine Pfizer BioNTech |
|
684 |
[GO] |
2022―Feb―18 |
COVID-19 Vaccine Pfizer BioNTech |
|
685 |
[GO] |
2022―Feb―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
686 |
[GO] |
2022―Feb―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
687 |
[GO] |
2022―Feb―18 |
Coronavirus-vaccine |
|
688 |
[GO] |
2022―Feb―18 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
689 |
[GO] |
2022―Feb―11 |
mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections |
|
690 |
[GO] |
2022―Feb―11 |
COVID-19 vaccine errors dominate ISMP's list of top 10 safety concerns for 2021 |
|
691 |
[GO] |
2022―Feb―11 |
Covid-19-vaccine-pfizer-biontech |
|
692 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
693 |
[GO] |
2022―Feb―11 |
Covid-19-vaccine-pfizer-biontech |
|
694 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
695 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
696 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
697 |
[GO] |
2022―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
698 |
[GO] |
2022―Feb―04 |
Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination |
|
699 |
[GO] |
2022―Feb―04 |
COVID-19 vaccine |
|
700 |
[GO] |
2022―Feb―04 |
Growing evidence reassuring for mRNA COVID-19 vaccines in pregnancy |
|
701 |
[GO] |
2022―Feb―04 |
COVID-19-vaccine |
|
702 |
[GO] |
2022―Feb―04 |
Covid-19-vaccine |
|
703 |
[GO] |
2022―Feb―04 |
Covid-19-vaccine |
|
704 |
[GO] |
2022―Jan―28 |
Reported rates of CVST due to COVID-19 vaccination rose after publicising these ADRs |
|
705 |
[GO] |
2022―Jan―28 |
Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event |
|
706 |
[GO] |
2022―Jan―28 |
Covid-19-vaccine-pfizer-biontech |
|
707 |
[GO] |
2022―Jan―28 |
Covid-19-vaccine-pfizer-biontech |
|
708 |
[GO] |
2022―Jan―28 |
Covid-19-vaccine-pfizer-biontech |
|
709 |
[GO] |
2022―Jan―28 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
710 |
[GO] |
2022―Jan―28 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
711 |
[GO] |
2022―Jan―28 |
Coronavirus-vaccine |
|
712 |
[GO] |
2022―Jan―28 |
Coronavirus-vaccine |
|
713 |
[GO] |
2022―Jan―21 |
COVID-19 vaccines safe in people living with HIV |
|
714 |
[GO] |
2022―Jan―21 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
715 |
[GO] |
2022―Jan―21 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
716 |
[GO] |
2022―Jan―21 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
717 |
[GO] |
2022―Jan―21 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
718 |
[GO] |
2022―Jan―14 |
Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant |
|
719 |
[GO] |
2022―Jan―14 |
Rare reports of rheumatic disorder flares after COVID-19 vaccination |
|
720 |
[GO] |
2022―Jan―14 |
Small change in menstrual cycle length after COVID-19 vaccination |
|
721 |
[GO] |
2022―Jan―14 |
Expected rates of adverse events after COVID-19 vaccination in USA |
|
722 |
[GO] |
2022―Jan―14 |
Covid-19-vaccine/tozinameran |
|
723 |
[GO] |
2022―Jan―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
724 |
[GO] |
2022―Jan―06 |
Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines |
|
725 |
[GO] |
2022―Jan―06 |
COVID-19 Vaccine Pfizer BioNTech |
|
726 |
[GO] |
2022―Jan―06 |
Signal for COVID-19 vaccine-related menstrual disorders |
|
727 |
[GO] |
2022―Jan―06 |
Systematic review: COVID-19 vaccine-related neurological disorders "exceedingly" rare |
|
728 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine |
|
729 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine |
|
730 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine |
|
731 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
732 |
[GO] |
2022―Jan―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
733 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine-pfizer-biontech |
|
734 |
[GO] |
2022―Jan―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
735 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine-pfizer-biontech |
|
736 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine-pfizer-biontech |
|
737 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine/influenza-virus-vaccine |
|
738 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine/mrna-1273 |
|
739 |
[GO] |
2022―Jan―06 |
SARS-COV-2 vaccine inactivated-Sinovac-Biotech |
|
740 |
[GO] |
2022―Jan―06 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
741 |
[GO] |
2022―Jan―06 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
742 |
[GO] |
2022―Jan―06 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
743 |
[GO] |
2021―Dec―18 |
COVID-19 Vaccine Pfizer-BioNTech |
|
744 |
[GO] |
2021―Dec―18 |
Most adolescent myocarditis cases related to covid-19 vaccines mild, resolve quickly |
|
745 |
[GO] |
2021―Dec―18 |
Covid-19-vaccine-pfizer-biontech |
|
746 |
[GO] |
2021―Dec―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
747 |
[GO] |
2021―Dec―18 |
Coronavirus vaccine |
|
748 |
[GO] |
2021―Dec―18 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
749 |
[GO] |
2021―Dec―18 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
750 |
[GO] |
2021―Dec―10 |
Safety of seven COVID-19 vaccine booster doses |
|
751 |
[GO] |
2021―Dec―10 |
Myocarditis, pericarditis with COVID-19 vaccines in the Netherlands |
|
752 |
[GO] |
2021―Dec―10 |
COVID-19 vaccines/rituximab |
|
753 |
[GO] |
2021―Dec―10 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
754 |
[GO] |
2021―Dec―10 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
755 |
[GO] |
2021―Dec―10 |
Covid-19-vaccine/immune-globulin/methylprednisolone |
|
756 |
[GO] |
2021―Dec―10 |
COVID-19-vaccines |
|
757 |
[GO] |
2021―Dec―10 |
Covid-19-vaccines/rituximab |
|
758 |
[GO] |
2021―Dec―10 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
759 |
[GO] |
2021―Dec―10 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
760 |
[GO] |
2021―Dec―04 |
Risk-benefit of AstraZeneca COVID-19 vaccination in Australia |
|
761 |
[GO] |
2021―Dec―04 |
No increase in stroke, MI or PE after Pfizer-BioNTech COVID-19 vaccine |
|
762 |
[GO] |
2021―Dec―04 |
Adverse reactions with Pfizer/BioNTech's COVID-19 vaccine in Ecuador |
|
763 |
[GO] |
2021―Dec―04 |
Pfizer-BioNTech COVID-19 vaccine safe in older Koreans |
|
764 |
[GO] |
2021―Dec―04 |
COVID-19-vaccine |
|
765 |
[GO] |
2021―Dec―04 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
766 |
[GO] |
2021―Dec―04 |
Covid-19-vaccine-pfizer-biontech |
|
767 |
[GO] |
2021―Dec―04 |
Covid-19-vaccine-pfizer-biontech |
|
768 |
[GO] |
2021―Dec―04 |
COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273 |
|
769 |
[GO] |
2021―Dec―04 |
Coronavirus-vaccine |
|
770 |
[GO] |
2021―Dec―04 |
Coronavirus-vaccine-Wuhan-Institute-of-Biological-Products |
|
771 |
[GO] |
2021―Nov―26 |
Cutaneous vasculitis following COVID-19 vaccination |
|
772 |
[GO] |
2021―Nov―26 |
COVID-19 vaccine Pfizer BioNTech |
|
773 |
[GO] |
2021―Nov―26 |
Possibility of mix-up with paediatric COVID-19 vaccines |
|
774 |
[GO] |
2021―Nov―26 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
775 |
[GO] |
2021―Nov―26 |
Covid-19-vaccine-pfizer-biontech |
|
776 |
[GO] |
2021―Nov―26 |
Covid-19-vaccine-pfizer-biontech |
|
777 |
[GO] |
2021―Nov―19 |
Myocarditis rare after COVID-19 mRNA vaccination |
|
778 |
[GO] |
2021―Nov―19 |
Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine |
|
779 |
[GO] |
2021―Nov―19 |
English-only labels for Janssen's COVID-19 vaccine in Canada |
|
780 |
[GO] |
2021―Nov―19 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
781 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-pfizer-biontech |
|
782 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-pfizer-biontech |
|
783 |
[GO] |
2021―Nov―19 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
784 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-pfizer-biontech |
|
785 |
[GO] |
2021―Nov―19 |
COVID-19-vaccine-pfizer-biontech/ibuprofen/oxycodone |
|
786 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-Pfizer-BioNTech/mRNA-1273 |
|
787 |
[GO] |
2021―Nov―05 |
COVID-19 vaccine |
|
788 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
789 |
[GO] |
2021―Nov―05 |
Covid-19-vaccine-pfizer-biontech |
|
790 |
[GO] |
2021―Nov―05 |
Covid-19-vaccine-pfizer-biontech |
|
791 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
792 |
[GO] |
2021―Nov―05 |
Covid-19-vaccine-pfizer-biontech |
|
793 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
794 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273 |
|
795 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech/mycophenolic acid/tacrolimus |
|
796 |
[GO] |
2021―Nov―05 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
797 |
[GO] |
2021―Oct―29 |
Covid-19-vaccine-pfizer-biontech |
|
798 |
[GO] |
2021―Oct―29 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
799 |
[GO] |
2021―Oct―29 |
Covid-19-vaccine/rituximab |
|
800 |
[GO] |
2021―Oct―22 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
801 |
[GO] |
2021―Oct―22 |
Covid-19-vaccine-pfizer-biontech |
|
802 |
[GO] |
2021―Oct―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
803 |
[GO] |
2021―Oct―16 |
Pfizer-BioNTech COVID-19 vaccine in patients with severe allergies |
|
804 |
[GO] |
2021―Oct―16 |
Covid-19-vaccine |
|
805 |
[GO] |
2021―Oct―16 |
COVID-19-vaccine |
|
806 |
[GO] |
2021―Oct―16 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
807 |
[GO] |
2021―Oct―16 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
808 |
[GO] |
2021―Oct―16 |
No evidence of birth defects or spontaneous abortion from pandemic H1N1-influenza vaccine |
|
809 |
[GO] |
2021―Oct―10 |
Covid-19 vaccine-Pfizer-Biontech |
|
810 |
[GO] |
2021―Oct―10 |
No association between COVID-19 vaccination and menstrual disorders |
|
811 |
[GO] |
2021―Oct―01 |
FAPIC score predicts mortality after COVID-19 vaccine-related TTS |
|
812 |
[GO] |
2021―Oct―01 |
Product monographs for COVID-19 vaccines updated in Canada |
|
813 |
[GO] |
2021―Oct―01 |
Covid-19-vaccine-pfizer-biontech |
|
814 |
[GO] |
2021―Oct―01 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
815 |
[GO] |
2021―Sep―24 |
COVID-19 vaccination safe during pregnancy |
|
816 |
[GO] |
2021―Sep―24 |
Covid-19-vaccine-pfizer-biontech |
|
817 |
[GO] |
2021―Sep―17 |
Minimal risk of GBS relapse after Pfizer-BioNTech COVID-19 vaccination |
|
818 |
[GO] |
2021―Sep―17 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
819 |
[GO] |
2021―Sep―17 |
COVID-19-Vaccine-Pfizer-BioNTech/ciclosporin/mycophenolate sodium |
|
820 |
[GO] |
2021―Sep―17 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
821 |
[GO] |
2021―Sep―12 |
Warnings of risks associated with ivermectin use for COVID-19 |
|
822 |
[GO] |
2021―Sep―12 |
mRNA-based vs viral vector-based COVID-19 vaccines |
|
823 |
[GO] |
2021―Sep―12 |
Covid-19-vaccine-pfizer-biontech |
|
824 |
[GO] |
2021―Sep―12 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
825 |
[GO] |
2021―Sep―12 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university |
|
826 |
[GO] |
2021―Sep―12 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
827 |
[GO] |
2021―Sep―04 |
Antihypertensives: sex differences in risk of COVID-19 |
|
828 |
[GO] |
2021―Sep―04 |
Thrombocytopenia and thromboembolism after COVID-19 vaccination |
|
829 |
[GO] |
2021―Sep―04 |
COVID-19 Vaccine Pfizer BioNTech |
|
830 |
[GO] |
2021―Sep―04 |
AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis |
|
831 |
[GO] |
2021―Sep―04 |
Covid-19-vaccine-Pfizer-BioNTech |
|
832 |
[GO] |
2021―Sep―04 |
Covid-19-vaccine-pfizer-biontech |
|
833 |
[GO] |
2021―Sep―04 |
Covid-19-vaccine-pfizer-biontech |
|
834 |
[GO] |
2021―Sep―04 |
Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab |
|
835 |
[GO] |
2021―Aug―27 |
Covid-19 vaccine pfizer biontech |
|
836 |
[GO] |
2021―Aug―27 |
Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents |
|
837 |
[GO] |
2021―Aug―27 |
Janssen COVID-19 vaccine-related tinnitus and dizziness |
|
838 |
[GO] |
2021―Aug―27 |
Covid-19-vaccine-Pfizer-BioNTech |
|
839 |
[GO] |
2021―Aug―21 |
COVID-19 vaccination encouraged by the EMA/ECDC |
|
840 |
[GO] |
2021―Aug―21 |
Pfizer-BioNTech COVID-19 vaccine label update on Bell's palsy in Canada |
|
841 |
[GO] |
2021―Aug―21 |
Cerebral vein thrombosis after four COVID-19 vaccines in Europe |
|
842 |
[GO] |
2021―Aug―21 |
Covid-19-vaccine-pfizer-biontech |
|
843 |
[GO] |
2021―Aug―21 |
Covid-19-vaccine-Pfizer-BioNTech/prednisone |
|
844 |
[GO] |
2021―Aug―21 |
Remdesivir vs tocilizumab in COVID-19: adverse event profiles |
|
845 |
[GO] |
2021―Aug―13 |
NSAIDs do not increase risk or severity of COVID-19 infections |
|
846 |
[GO] |
2021―Aug―13 |
Cerebral venous sinus thrombosis after COVID-19 vaccination |
|
847 |
[GO] |
2021―Aug―13 |
Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan |
|
848 |
[GO] |
2021―Aug―13 |
PRAC meeting 5 August 2021: COVID-19 vaccine safety issues |
|
849 |
[GO] |
2021―Aug―13 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
850 |
[GO] |
2021―Aug―13 |
Covid-19-vaccine-pfizer-biontech |
|
851 |
[GO] |
2021―Aug―13 |
Covid-19-Vaccine-Pfizer-Biontech |
|
852 |
[GO] |
2021―Aug―13 |
Covid-19-vaccine-pfizer-biontech/levofloxacin |
|
853 |
[GO] |
2021―Aug―09 |
WHO GACVS reviews cases of GBS after COVID-19 vaccination |
|
854 |
[GO] |
2021―Aug―09 |
Rolling review of COVID-19 vaccine Vidprevtyn by EMA |
|
855 |
[GO] |
2021―Aug―09 |
Revisions of precautions for COVID-19 vaccines and other drugs in Japan |
|
856 |
[GO] |
2021―Aug―09 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
857 |
[GO] |
2021―Aug―09 |
Covid-19-vaccine-pfizer-biontech |
|
858 |
[GO] |
2021―Aug―01 |
EMA assessing safety of anakinra in adults with COVID-19 |
|
859 |
[GO] |
2021―Aug―01 |
PMDA: precautions should be revised for Covid-19 vaccine |
|
860 |
[GO] |
2021―Jul―23 |
Warning for Janssen COVID-19 vaccine: risk of Guillain-Barré syndrome |
|
861 |
[GO] |
2021―Jul―23 |
PRAC meeting highlights July 2021: Zynteglo and COVID-19 vaccines |
|
862 |
[GO] |
2021―Jul―23 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
863 |
[GO] |
2021―Jul―23 |
Covid-19-vaccine-pfizer-biontech |
|
864 |
[GO] |
2021―Jul―17 |
AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome |
|
865 |
[GO] |
2021―Jul―05 |
Myocarditis or pericarditis following COVID-19 vaccination |
|
866 |
[GO] |
2021―Jul―05 |
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine |
|
867 |
[GO] |
2021―Jul―05 |
COVID-19-vaccine-pfizer-biontech |
|
868 |
[GO] |
2021―Jul―05 |
Covid-19-vaccines |
|
869 |
[GO] |
2021―Jun―26 |
FDA reports recall of Innova COVID-19 antigen rapid qualitative test |
|
870 |
[GO] |
2021―Jun―26 |
Myocarditis and pericarditis after COVID-19 vaccination |
|
871 |
[GO] |
2021―Jun―26 |
PRAC June 2021 meeting highlights: COVID-19 vaccine AEs |
|
872 |
[GO] |
2021―Jun―26 |
US-labelled supply of Moderna's COVID-19 vaccine in Cananda |
|
873 |
[GO] |
2021―Jun―18 |
Biological or targeted synthetic DMARDs increase COVID-19 severity |
|
874 |
[GO] |
2021―Jun―18 |
Pfizer-BioNtech's COVID-19 vaccine approved for younger adolescents |
|
875 |
[GO] |
2021―Jun―18 |
Safeguarding against use of contaminated COVID-19 Vaccine Janssen |
|
876 |
[GO] |
2021―Jun―18 |
Heterogeneity in potential COVID-19 vaccine-related AEs |
|
877 |
[GO] |
2021―Jun―18 |
EMA advice on COVID-19 vaccine-related thrombosis with thrombocytopenia |
|
878 |
[GO] |
2021―Jun―12 |
Nursing home resident deaths after Pfizer-BioNTech's COVID-19 vaccine |
|
879 |
[GO] |
2021―Jun―12 |
Many Danes with fever after COVID-19 vaccine would contact doctor |
|
880 |
[GO] |
2021―Jun―05 |
Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines |
|
881 |
[GO] |
2021―Jun―05 |
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines |
|
882 |
[GO] |
2021―Jun―05 |
COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab |
|
883 |
[GO] |
2021―May―28 |
Bleeding and clotting with AstraZeneca's COVID-19 vaccine |
|
884 |
[GO] |
2021―May―28 |
Updated advice on thrombosis with thrombocytopenia syndrome and use of COVID-19 Vaccine AstraZeneca |
|
885 |
[GO] |
2021―May―21 |
COVID-19 vaccination during pregnancy: no increase in placental lesions |
|
886 |
[GO] |
2021―May―21 |
PRAC May 2021 meeting highlights: COVID-19 vaccine AEs |
|
887 |
[GO] |
2021―May―21 |
Do NSAIDs increase the severity of COVID-19? |
|
888 |
[GO] |
2021―May―14 |
COVID-19 vaccination errors in USA reported to ISMP |
|
889 |
[GO] |
2021―May―14 |
TTS with Janssen's COVID-19 vaccine |
|
890 |
[GO] |
2021―May―14 |
Anxiety disorders with Janssen's COVID-19 vaccine |
|
891 |
[GO] |
2021―May―14 |
AstraZeneca COVID-19 vaccine-related thromboembolism |
|
892 |
[GO] |
2021―May―14 |
AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea |
|
893 |
[GO] |
2021―May―07 |
No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine |
|
894 |
[GO] |
2021―May―07 |
FDA and CDC recommend resuming use of Janssen COVID-19 vaccine |
|
895 |
[GO] |
2021―May―07 |
COVID-19 vaccine adverse events reported via app |
|
896 |
[GO] |
2021―May―07 |
AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia |
|
897 |
[GO] |
2021―May―07 |
New EMA/ECDC initiative for monitoring COVID-19 vaccines |
|
898 |
[GO] |
2021―May―03 |
PRAC: blood clots with Janssen's COVID-19 vaccine |
|
899 |
[GO] |
2021―May―03 |
Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD |
|
900 |
[GO] |
2021―Apr―23 |
FDA remote evaluation of drug manufacturing during COVID-19 |
|
901 |
[GO] |
2021―Apr―23 |
Health Canada: blood clots with AstraZeneca's COVID-19 vaccine |
|
902 |
[GO] |
2021―Apr―23 |
Denmark ceases roll out of AstraZeneca's COVID-19 vaccine |
|
903 |
[GO] |
2021―Apr―23 |
COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets |
|
904 |
[GO] |
2021―Apr―23 |
PRAC: blood clots or capillary leak syndrome with COVID-19 vaccines |
|
905 |
[GO] |
2021―Apr―23 |
Health Canada: AKI or ARF with remdesivir for COVID-19? |
|
906 |
[GO] |
2021―Apr―16 |
Should cancer patients receiving ICIs received COVID-19 vaccination? |
|
907 |
[GO] |
2021―Apr―16 |
Pfizer-BioNTech COVID-19 vaccine: AEs after vaccination in New Zealand |
|
908 |
[GO] |
2021―Apr―16 |
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia |
|
909 |
[GO] |
2021―Apr―10 |
Falsified COVID-19 vaccine recently identified in Mexico |
|
910 |
[GO] |
2021―Apr―10 |
AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots |
|
911 |
[GO] |
2021―Apr―10 |
AstraZeneca COVID-19 vaccine: no increased rate of VTE |
|
912 |
[GO] |
2021―Apr―02 |
No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine |
|
913 |
[GO] |
2021―Apr―02 |
Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots |
|
914 |
[GO] |
2021―Apr―02 |
AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada |
|
915 |
[GO] |
2021―Mar―26 |
Universal COVID-19 vaccination cost saving unless anaphylaxis rate high |
|
916 |
[GO] |
2021―Mar―26 |
Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine |
|
917 |
[GO] |
2021―Mar―26 |
Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots |
|
918 |
[GO] |
2021―Mar―26 |
March 2021 PRAC meeting highlights include COVID-19 vaccine update |
|
919 |
[GO] |
2021―Mar―26 |
COVID-19-vaccine-Pfizer-BioNTech |
|
920 |
[GO] |
2021―Mar―19 |
COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis |
|
921 |
[GO] |
2021―Mar―19 |
Reports of flu-like symptoms after COVID-19 vaccination |
|
922 |
[GO] |
2021―Mar―19 |
EMA assessing cases of blood clots after AstraZeneca COVID-19 vaccine |
|
923 |
[GO] |
2021―Mar―19 |
COVID-19 vaccine AE reports in Australia and New Zealand |
|
924 |
[GO] |
2021―Mar―13 |
Vial and carton labelling updated for Moderna COVID-19 vaccine |
|
925 |
[GO] |
2021―Mar―13 |
COVID-19 vaccine-related lymphadenopathy may affect breast screening |
|
926 |
[GO] |
2021―Feb―26 |
COVID-19 vaccine safety monitoring |
|
927 |
[GO] |
2021―Feb―19 |
Second HPRA safety update on COVID-19 vaccines |
|
928 |
[GO] |
2021―Feb―12 |
MHRA Yellow Card reports on COVID-19 vaccine adverse reactions |
|
929 |
[GO] |
2021―Feb―12 |
Safety update on COVID-19 vaccine Comirnaty finds no new concerns |
|
930 |
[GO] |
2021―Feb―05 |
Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19 |
|
931 |
[GO] |
2021―Feb―05 |
WHO considers Pfizer BioNTech COVID-19 vaccine safe in elderly |
|
932 |
[GO] |
2021―Feb―05 |
HPRA safety update on BioNTech and Moderna COVID-19 vaccines |
|
933 |
[GO] |
2021―Jan―29 |
Norway advised to assess the very frail prior to COVID-19 vaccination |
|
934 |
[GO] |
2021―Jan―29 |
Moderna COVID-19 vaccine: 2.5 cases of anaphylaxis per million doses |
|
935 |
[GO] |
2021―Jan―29 |
ISMP reports: errors or hazards with COVID-19 vaccines |
|
936 |
[GO] |
2021―Jan―29 |
NSAID use does not increase risk of COVID-19-related death |
|
937 |
[GO] |
2021―Jan―22 |
Deaths in frail patients after Pfizer/BioNTech COVID-19 vaccination |
|
938 |
[GO] |
2021―Jan―22 |
Advice on COVID-19 vaccines approved in UK by MHRA |
|
939 |
[GO] |
2021―Jan―22 |
Safety of COVID-19 vaccines: who should see an allergist |
|
940 |
[GO] |
2021―Jan―21 |
Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis |
|
941 |
[GO] |
2021―Jan―08 |
Pfizer COVID-19-related drug use and safety surveillance |
|
942 |
[GO] |
2021―Jan―06 |
Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine |
|
943 |
[GO] |
2020―Dec―21 |
COVID-19-related deaths not increased with ACE inhibitor or ARB use |
|
944 |
[GO] |
2020―Dec―11 |
EMA and ICMRA urge continuation of COVID-19 vaccine safety trials |
|
945 |
[GO] |
2020―Nov―27 |
EMA's safety monitoring plan for COVID-19 vaccines |
|
946 |
[GO] |
2020―Nov―20 |
Drug-drug interactions in patients with COVID-19 |
|
947 |
[GO] |
2020―Nov―13 |
EMA guidance on risk management plans for COVID-19 vaccines reviewed |
|
948 |
[GO] |
2020―Nov―06 |
Quality of ADR reporting evaluated for remdesivir trials of COVID-19 |
|
949 |
[GO] |
2020―Nov―06 |
Hydroxychloroquine-related psychiatric disorders in COVID-19 patients |
|
950 |
[GO] |
2020―Nov―06 |
Phase III trial of Covid-19 treatment paused for safety concerns |
|
951 |
[GO] |
2020―Nov―06 |
Concerns raised with MHRA of anticoagulant use during pandemic |
|
952 |
[GO] |
2020―Oct―16 |
Remdesivir-related acute kidney injury in patients with COVID-19 |
|
953 |
[GO] |
2020―Oct―02 |
Sex differences in ADR reports for drugs used to treat COVID-19 |
|
954 |
[GO] |
2020―Aug―14 |
Proton pump inhibitors increase risk of COVID-19 |
|
955 |
[GO] |
2020―Aug―14 |
Health Canada approves first drug for treatment of COVID-19 |
|
956 |
[GO] |
2020―Jul―24 |
Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients |
|
957 |
[GO] |
2020―Jul―17 |
Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality |
|
958 |
[GO] |
2020―Jun―26 |
New potential interaction with emergency COVID-19 medicine remdesivir |
|
959 |
[GO] |
2020―Jun―12 |
Benefit-risk assessment for remdesivir in COVID-19 |
|
960 |
[GO] |
2020―Jun―12 |
Risks of chloroquine or hydroxychloroquine use for COVID-19 |
|
961 |
[GO] |
2020―Jun―05 |
COVID-19 pregnancy prevention guidance on teratogenic drugs |
|
962 |
[GO] |
2020―Jun―05 |
UK's MHRA publishes guidance for valproate PPP during pandemic |
|
963 |
[GO] |
2020―May―29 |
Chloroquine and hydroxychloroquine increase risk of death in COVID-19 |
|
964 |
[GO] |
2020―May―29 |
Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic |
|
965 |
[GO] |
2020―May―29 |
Cardiac adverse reactions with off-label Covid-19 treatments |
|
966 |
[GO] |
2020―May―23 |
US guidance issued for postmarketing AE reporting during pandemic |
|
967 |
[GO] |
2020―May―18 |
International Society of Pharmacovigilance: COVID-19 role |
|
968 |
[GO] |
2020―May―18 |
MHRA COVID-19 website for reporting ADRs and incidents |
|
969 |
[GO] |
2020―May―18 |
Risk of Covid-19 with renin-angiotensin-aldosterone system medications |
|
970 |
[GO] |
2020―May―11 |
Evaluation of potential therapies for COVID-19 global pandemic |
|
971 |
[GO] |
2020―May―11 |
Demand for potentially hazardous COVID-19 treatments |
|
972 |
[GO] |
2020―May―11 |
UMC: use appropriate COVID-19-related terms for ICSRs |
|
973 |
[GO] |
2020―May―04 |
ACEI inhibitors and ARBs do not increase severity of COVID-19 |
|
974 |
[GO] |
2020―May―04 |
Safety concerns with higher dosage chloroquine in COVID-19 patients |
|
975 |
[GO] |
2020―May―04 |
High incidence of ADRs in COVID-19 patients in China |
|
976 |
[GO] |
2020―May―04 |
Antimalarial use in COVID-19 patients requires close monitoring |
|
977 |
[GO] |
2020―Apr―20 |
EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic |
|
978 |
[GO] |
2020―Apr―06 |
Regulatory agencies issue advice on use of NSAIDs for COVID-19 |
|